ATE512147T1 - Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer - Google Patents

Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer

Info

Publication number
ATE512147T1
ATE512147T1 AT05849049T AT05849049T ATE512147T1 AT E512147 T1 ATE512147 T1 AT E512147T1 AT 05849049 T AT05849049 T AT 05849049T AT 05849049 T AT05849049 T AT 05849049T AT E512147 T1 ATE512147 T1 AT E512147T1
Authority
AT
Austria
Prior art keywords
treatment
macrocyclic
alzheimer
disease
aminiopyridyl
Prior art date
Application number
AT05849049T
Other languages
English (en)
Inventor
Hemaka Rajapakse
Philippe Nantermet
Harold Selnick
Keith Moore
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE512147T1 publication Critical patent/ATE512147T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT05849049T 2004-11-23 2005-11-18 Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer ATE512147T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63031904P 2004-11-23 2004-11-23
PCT/US2005/042233 WO2006057983A1 (en) 2004-11-23 2005-11-18 Macrocyclic aminopyridyl beta-secretase inhibitors for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
ATE512147T1 true ATE512147T1 (de) 2011-06-15

Family

ID=36498305

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05849049T ATE512147T1 (de) 2004-11-23 2005-11-18 Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer

Country Status (8)

Country Link
US (1) US7951949B2 (de)
EP (1) EP1817312B1 (de)
JP (1) JP2008520727A (de)
CN (1) CN101061119A (de)
AT (1) ATE512147T1 (de)
AU (1) AU2005309708A1 (de)
CA (1) CA2587256A1 (de)
WO (1) WO2006057983A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7678783B2 (en) 2004-11-17 2010-03-16 Merck Sharp & Dohme Corp. Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
CA2667071A1 (en) * 2006-10-06 2008-04-17 Merck & Co., Inc. Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
EP2117540A1 (de) 2007-03-01 2009-11-18 Probiodrug AG Neue verwendung von glutaminyl-cyclase-hemmern
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
CN104263795A (zh) * 2014-08-22 2015-01-07 四川同晟生物科技有限公司 制备手性α-环烷基甘氨酸的方法
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001229320A1 (en) 2000-01-12 2001-07-24 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
CA2450167A1 (en) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
WO2003106405A1 (en) 2002-06-01 2003-12-24 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
WO2004043916A1 (en) 2002-11-12 2004-05-27 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
US7371853B2 (en) 2003-01-07 2008-05-13 Merck & Co., Inc. Macrocyclic β-secretase inhibitors for the treatment of Alzheimer's disease
EP1644322A1 (de) 2003-06-16 2006-04-12 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitoren
AU2004255183A1 (en) 2003-06-30 2005-01-20 Merck & Co., Inc. N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of Alzheimer's disease
WO2005004803A2 (en) 2003-07-01 2005-01-20 Merck & Co., Inc. Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
CN1835936A (zh) 2003-08-14 2006-09-20 默克公司 用于治疗阿尔茨海默氏病的大环β-分泌酶抑制剂
DE602004014170D1 (de) 2003-10-03 2008-07-10 Merck & Co Inc Benzylether- und benzylamino-beta-sekretase-hemmer zur behandlung von alzheimer-krankheit
ATE517861T1 (de) 2003-11-24 2011-08-15 Merck Sharp & Dohme Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EP1697308B1 (de) 2003-12-19 2014-03-19 Merck Sharp & Dohme Corp. Phenylamid- und pyridylamid-beta-sekretase-inhibitoren zur behandlung von alzheimer-krankheit
EP1740559B1 (de) 2004-04-20 2014-10-15 Merck Sharp & Dohme Corp. Als beta-sekretase-inhibitoren für die behandlung von alzheimer-krankheit geeignete 1,3,5-substituierte phenylderivatverbindungen
JP4764418B2 (ja) 2004-04-20 2011-09-07 メルク・シャープ・エンド・ドーム・コーポレイション アルツハイマー病の治療のためのβ−セクレターゼ阻害剤として有用な2,4,6−置換ピリジル誘導体化合物
US20070298029A1 (en) * 2004-08-09 2007-12-27 Carsten Hopf Treatment of Neurodegenerative Diseases by the Use of Degs Inhibitors
US7678783B2 (en) 2004-11-17 2010-03-16 Merck Sharp & Dohme Corp. Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
US20080015213A1 (en) 2008-01-17
EP1817312A4 (de) 2009-11-04
EP1817312A1 (de) 2007-08-15
EP1817312B1 (de) 2011-06-08
AU2005309708A1 (en) 2006-06-01
US7951949B2 (en) 2011-05-31
CA2587256A1 (en) 2006-06-01
WO2006057983A1 (en) 2006-06-01
CN101061119A (zh) 2007-10-24
JP2008520727A (ja) 2008-06-19

Similar Documents

Publication Publication Date Title
ATE512147T1 (de) Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
WO2006057945A3 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE555116T1 (de) Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
WO2007019078A3 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties